DTI Study of the Influence of Physiotherapy on Distribution of BoNT in Spastic Muscle
NCT01523210 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5
Last updated 2012-11-14
Summary
Intramuscular application of botulinum toxin (BoNT) is used as a successful therapy of muscle spasticity. Clinical practice shows, that even with the use of special guidance techniques to increase accuracy of targeting, BoNT may spread to adjacent sites by diffusion. This causes fluctuating treatment response, unintended side effects, and decrease of effect due to production of antibodies. Hence, clinicians require increase of efficacy and safety by dose reduction, improvement of injection technique, and additional treatment strategies. Referring to this, animal model showed increased efficacy and decreased systemic side effects of BoNT in the injected muscle after active or passive manipulation of muscle. The mechanism of this effect remain unclear.
T2 and (Diffusion Tensor Imaging) DTI technique can evaluate the in-vivo distribution of fluids in human skeletal muscle. In addition, it allows to differentiate denervated muscle tissue, caused by BoNT injections, from surrounding unaffected muscle tissue.
Up to the investigators knowledge, neither a human, in vivo measurement of the influence of passive muscle activity on the area of denervation, nor the primary, in-vivo distribution of BoNT within spastic human muscle tissue, been evaluated.
The aim of this explorative study is:
* to monitor the inflow and regional distribution of the injection bolus by dynamic T2-weighted-, DTI-sequences;
* to assess the effect of passive muscle exercise on the area of denervated, caused by BoNT, measured by DTI-, T2-weighted and flair sequences.
The investigators hypothesize, that
* intramuscular denervation area, measured by DTI-, T2-weighted and Fluid Attenuated Inversion Recovery (FLAIR) sequences, 3 weeks after routine BoNT injection, is facilitated by passive muscle exercise;
* primary distribution of the injected BoNT bolus can be non-invasively monitored by dynamic T2-, DTI- and T2 weighted sequences.
Therefore, in this investigator blinded, cross-over study, 6 patients suffering from upper limb spasticity, including musculus biceps brachii, will be investigated. (Magnetic Resonance Tomography) MRI of the musculus biceps brachii will be performed at two consecutive, routine BoNT-injection days (baseline and week 16). Patients receive dosage as clinically indicated, due to routine treatment. Patients will be randomised to receive thirty minutes of physiotherapy of the affected arm, including exercise of the elbow flexors, at one of the injection days (baseline, or week 16, respectively). In addition, MRI will be repeated 3 weeks after injection.
Conditions
- Spasticity
Interventions
- OTHER
-
physiotherapy
thirty minutes passive flexion and extension of the elbow joint by a physiotherapist
Sponsors & Collaborators
-
Kirsten Elwischger, MD
lead OTHER
Principal Investigators
-
Thomas Sycha, Prof., MD · Medical University of Vienna, Department of Neurology
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-11-30
- Primary Completion
- 2012-11-30
- Completion
- 2012-11-30
Countries
- Austria
Study Locations
More Related Trials
-
Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings
NCT03302741 ·Status: COMPLETED ·Phase: PHASE4
-
Physiotherapy and Botox for Cervical Dystonia: Impact of Sensory Tricks and Brain Imaging Insights
NCT06881147 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Muscle Elastography in Spastic Cerebral Palsy
NCT03112434 ·Status: COMPLETED
-
Exploring Advanced Imaging Techniques to Characterize Botulinum Toxin Diffusion in Human Muscle
NCT01412008 ·Status: COMPLETED ·Phase: NA
-
Botulinum Toxin Injection Efficiency
NCT01041157 ·Status: UNKNOWN ·Phase: PHASE1
-
Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
NCT01387074 ·Status: COMPLETED
-
Factors Determining the Efficacy of Botulinum Toxin for Arm Tremor in Dystonia
NCT06411028 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm
NCT01603459 ·Status: COMPLETED ·Phase: PHASE3
-
Does ESWT With BoNTA Treatment Improve Outcomes When Compared to Standard Management for Upper Limb Spasticity Patient.
NCT05226637 ·Status: RECRUITING ·Phase: NA
-
Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles
NCT00133861 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity
NCT02275312 ·Status: COMPLETED
-
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
NCT01392300 ·Status: COMPLETED ·Phase: PHASE3
-
Changes in Echogenicity and Muscle Stiffness in Elastography After Botulinum Toxin Injection a Spastic Muscle
NCT02550509 ·Status: TERMINATED ·Phase: NA
-
Neurotoxin and Physical Therapy
NCT02177617 ·Status: COMPLETED ·Phase: PHASE4
-
Botulinum Toxin A & Weekly Serial Casting in ABI Inpatients With Lower Extremity Spasticity
NCT03903653 ·Status: WITHDRAWN ·Phase: PHASE2
-
Botox for the Treatment of Chronic Exertional Compartment Syndrome
NCT03922139 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain
NCT00178945 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effects of Botulinum Toxin on Muscle and Brain Activity
NCT02837185 ·Status: TERMINATED ·Phase: NA
-
Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia
NCT00432341 ·Status: TERMINATED ·Phase: PHASE4
-
Outcome of Botulinum Toxin Treatment for Oromandibular Dystonia
NCT03363113 ·Status: COMPLETED
-
Early Use of Botulinum Toxin in Spasticity Post Stroke.
NCT01882556 ·Status: COMPLETED ·Phase: PHASE2
-
Trial Comparing Two Commercial Formulations of Botulinum Toxin Type A in the Treatment of Spasticity
NCT00819065 ·Status: COMPLETED ·Phase: PHASE3
-
Study Assessing Adult Subjects Affected With Upper and/or Lower Limb Spasticity Treated With Botulinum Neurotoxin Type A
NCT04340336 ·Status: COMPLETED
-
Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity
NCT03017729 ·Status: COMPLETED
-
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
NCT01575054 ·Status: COMPLETED ·Phase: PHASE3